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DELAYING PROGRESSION OF CKD
The following section describes key recommendations and
guidance for people with CKD with respect to delaying
progression of CKD. General lifestyle recommendations are
provided as well as caveats given for those with diabetes.
Cardiovascular risk reduction including management of
hypertension, dyslipidemia, and hyperuricemia is further
addressed. Unless otherwise stated, the guidance is intended
to apply to adults with CKD.
For the practicing clinician, ideally working with a team of
health-care professionals, it is important to institute general
lifestyle modification practices in people with CKD so that
they may gain the benefit of these in addition to more
kidney-specific strategies. Often these general measures are
overlooked or disregarded in people with CKD, thus their
utility is underscored here.
3.1 PREVENTION OF CKD PROGRESSION
The management of progression of CKD is aimed at
addressing a multiplicity of factors known to be associated
with progression. There are general measures which have
been shown to address cardiovascular health and CKD
together, or each separately. Addressing CVD risk factors may
indirectly and directly impact CKD progression. Strategies
include general lifestyle measures which improve cardio-
vascular health, BP control, and interruption of the RAAS.
In addition, control of other metabolic parameters such as
blood sugar, uric acid, acidosis, and dyslipidemia may also be
important. This section deals with management of BP, RAAS
interruption, glycemic control and dietary/lifestyle mani-
pulations which have been examined in the context of
delaying progression of CKD.
BP and RAAS interruption
The following statements are excerpted and where
necessary, condensed, from the KDIGO Clinical Practice
Guideline for the Management of Blood Pressure in CKD.10
3.1.1: Individualize BP targets and agents according to age,
coexistent cardiovascular disease and other comorbid-
ities, risk of progression of CKD, presence or absence
of retinopathy (in CKD patients with diabetes), and
tolerance of treatment as described in the KDIGO
2012 Blood Pressure Guideline. (Not Graded)
3.1.2: Inquire about postural dizziness and check for
postural hypotension regularly when treating CKD
patients with BP-lowering drugs. (Not Graded)
3.1.3: Tailor BP treatment regimens in elderly patients with
CKD by carefully considering age, comorbidities and
other therapies, with gradual escalation of treatment
and close attention to adverse events related to BP
treatment, including electrolyte disorders, acute
deterioration in kidney function, orthostatic hypoten-
sion and drug side effects. (Not Graded)
3.1.4: We recommend that in both diabetic and non-
diabetic adults with CKD and urine albumin
excretion o30mg/24 hours (or equivalent*) whose
office BP is consistently 4140mm Hg systolic or
490mm Hg diastolic be treated with BP-lowering
drugs to maintain a BP that is consistentlyr140mm
Hg systolic and r90mm Hg diastolic. (1B)
3.1.5: We suggest that in both diabetic and non-diabetic
adults with CKD and with urine albumin excre-
tion of Z30mg/24 hours (or equivalent*) whose
office BP is consistently 4130mm Hg systolic or
480mm Hg diastolic be treated with BP-lowering
drugs to maintain a BP that is consistentlyr130mm
Hg systolic and r80mm Hg diastolic. (2D)
3.1.6: We suggest that an ARB or ACE-I be used in dia-
betic adults with CKD and urine albumin excretion
30-300mg/24 hours (or equivalent*). (2D)
3.1.7: We recommend that an ARB or ACE-I be used in
both diabetic and non-diabetic adults with CKD
and urine albumin excretion 4300mg/24 hours
(or equivalent*). (1B)
3.1.8: There is insufficient evidence to recommend com-
bining an ACE-I with ARBs to prevent progression
of CKD. (Not Graded)
3.1.9: We recommend that in children with CKD, BP-
lowering treatment is started when BP is consistently
above the 90th percentile for age, sex, and height. (1C)
3.1.10: We suggest that in children with CKD (particularly
those with proteinuria), BP is lowered to consistently
achieve systolic and diastolic readings less than or
equal to the 50th percentile for age, sex, and height,
unless achieving these targets is limited by signs or
symptoms of hypotension. (2D)
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*Approximate equivalents for albumin excretion rate per 24 hours—
expressed as protein excretion rate per 24 hours, albumin-to-creatinine
ratio, protein-to-creatinine ratio, and protein reagent strip results— are given
in Table 7, Chapter 1
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3.1.11: We suggest that an ARB or ACE-I be used in children
with CKD in whom treatment with BP-lowering
drugs is indicated, irrespective of the level of protein-
uria. (2D)
These statements are worded to maintain consistency with
the KDIGO Clinical Practice Guideline for the Management of
Blood Pressure in CKD,10 where the full rationale and
evidence behind the statements may be found. In detailing
BP targets, we recognize that we have not made recommen-
dations or suggestions concerning lower limits of BP. The
risks of overtreatment should be specifically considered when
making decisions about BP lowering and this is encapsulated
in the first two guideline statements.
CKD and risk of AKI
3.1.12: We recommend that all people with CKD are
considered to be at increased risk of AKI. (1A)
3.1.12.1: In people with CKD, the recommendations
detailed in the KDIGO AKI Guideline
should be followed for management of
those at risk of AKI during intercurrent
illness, or when undergoing investigation
and procedures that are likely to increase
the risk of AKI. (Not Graded)
RATIONALE
Observational data suggest a strong association between pre-
existing CKD and AKI. The appreciation that CKD patients
may be more susceptible to AKI is the purpose of the above set
of statements. However, methodological issues such as how
CKD and AKI are defined in clinical studies and the statistical
adjustments for non-uniformity of comorbidities among
various studies may affect the validity of observed associations.
These statements would be applicable in pediatrics, though the
data are not available for this specific issue.
Evidence Base
CKD is designated as a risk factor for AKI because of the
epidemiological association between the two.263,264 A number of
studies in a variety of settings report an association between
pre-existing CKD and AKI.265–271 CKD is a potent predictor of
acute decline in kidney function following exposure to radio-
contrast,272 major surgery,273 and other medical conditions.274
Hsu et al.14 compared the pre-hospitalization MDRD GFR
of 1764 adult members of the Kaiser Permanente Northern
California health-care system who developed dialysis-requir-
ing AKI during hospitalization with 600,820 individuals who
did not. Compared with a reference baseline GFR ofZ60ml/
min/1.73 m2, a baseline GFR of 45–59ml/min/1.73 m2 was
associated with an adjusted odds ratio (OR) of in-hospital
AKI of 1.66 (95% CI 1.40–1.97). For GFR values of 15–29ml/
min/1.73 m2, the adjusted OR for in-hospital AKI was 20.42
(95% CI 17.40–23.96). The presence of diabetes, hyperten-
sion, and proteinuria increased the likelihood of developing
in-hospital AKI, with adjusted OR of 1.99 (95% CI
1.78–2.23), 1.55 (95% CI 1.37–1.76) and 2.84 (95% CI
2.52–3.19), respectively. The authors concluded that CKD is
the main risk factor for AKI during hospitalization. A
contrasting approach by Singh et al. defined AKI as dialysis-
requiring acute renal failure.275 Because the clinical decision
to dialyze a patient is frequently influenced by a higher
overall SCr, presence of hemodialysis access, or consideration
of inevitable progression to ESRD, this definition of AKI
could bias toward capturing more AKI cases in CKD patients.
Moreover, in patients with advanced CKD, the progression of
CKD to ESRD may sometimes be difficult to separate from
acute-on-chronic renal failure. A cohort study by Lafrance
et al. followed a referred CKD population in British
Columbia for a median of 19.4 months after achieving a
GFR of r30ml/min/1.73 m2. Forty-five percent had at least
one episode of AKI.276 In another cohort study of 920,985
adults in Alberta, Canada with at least one outpatient
measurement of SCr and proteinuria and not requiring
chronic dialysis, risk of admission with AKI increased with
heavier proteinuria and reduced GFR.16
International Relevance
The incidence of AKI in CKD populations may be different
around the world, or have different etiologies. It is not yet
clear what the recovery rates from AKI are in the CKD
population, and how these vary around the world dependent
on cause and duration of AKI.
Areas of Controversy, Confusion, or Non-consensus
Interpretation of published data examining the influence
of pre-existing CKD on the increased likelihood of AKI
is potentially confounded by a number of issues. These
include the comorbidities associated with CKD, influenced
by repeated exposure to various nephrotoxic insults or
in-hospital errors,57,277 or primarily due to the altered
physiology in CKD. There are also methodological issues
such as how CKD and AKI are defined in clinical studies and
the varying statistical adjustments for comorbidities.
A further important issue to clarify is whether pre-existing
CKD influences the outcome of AKI. Currently, there is no
single biomarker that can differentiate ‘acute’ from ‘chronic’
kidney disease and help to address this issue. Several large
observational and database studies report, surprisingly, lower
in-hospital mortality in patients with AKI superimposed on
CKD compared with controls.278–283 Data from the Program
to Improve Care in Acute Renal Disease (PICARD) reveal
lower in-patient mortality and median length of stay in
intensive-care unit (ICU) subjects with acute-on-chronic
renal injury compared with non-CKD subjects with AKI,
though the post-discharge dialysis rates were higher in
subjects with pre-existing CKD.284
Clarification of Issues and Key Points
AKI is relatively common in CKD populations and impacts
progression adversely. Clinicans should attempt to minimize
74 Kidney International Supplements (2013) 3, 73–90
chapte r 3
avoidable episodes of AKI (see Chapter 4 for more details) as
part of a holistic approach to delaying progression.
RESEARCH RECOMMENDATIONS
Prospectively designed clinical studies with a clear and
uniform definition of CKD and AKI and adjusted for
comorbidities are needed to determine the:
K frequency of AKI events in a CKD population;
K outcome of AKI in patients with CKD;
K importance of proteinuria in addition to low GFR in the
risk of AKI.
Protein intake
3.1.13: We suggest lowering protein intake to 0.8 g/kg/day
in adults with diabetes (2C) or without diabetes
(2B) and GFR o30ml/min/ 1.73 m2 (GFR cate-
gories G4-G5), with appropriate education.
3.1.14: We suggest avoiding high protein intake (41.3 g/
kg/day) in adults with CKD at risk of progres-
sion. (2C)
RATIONALE
These statements are worded to reflect the potential benefits
and dangers of varying dietary protein intake (DPI) in people
with CKD. Excess dietary protein leads to the accumulation
of uremic toxins, conversely insufficient protein intake may
lead to loss of lean body mass, and malnutrition (the latter
more frequent in the elderly). The benefits of dietary protein
restriction include reduction of accumulation of metabolic
waste products that may suppress the appetite and stimulate
muscle protein wasting. The role of dietary protein restric-
tion in slowing progression of CKD is more controversial and
advanced CKD is associated with a protein wasting syndrome
which is directly correlated with morbidity and mortality.
Note that statements about reduction in dietary protein do
not apply to pediatric populations given issues related to
growth and nutrition.
Evidence Base
A number of systematic reviews and meta-analyses have
pooled the available RCT data.285–289 Pedrini et al.288
compared a low-protein diet (LPD), defined as a DPI of
0.4 to 0.6 g/kg/day, with a usual diet (5 RCTs, N¼ 1413) over
a period of follow-up ranging between 18-36 months in
people with non-diabetic CKD and GFRo55ml/min/1.73 m2.
Fouque et al.285 updated this analysis to include 8 RCTs
in people with non-diabetic CKD (N¼ 1524). DPI in
their low-protein group was between 0.3-0.6 g/kg/day and
follow-up ranged from 12-24 months (5 of 8 studies were in
people with GFR categories G4-G5 (GFR o30ml/min/
1.73 m2). Roberston et al.289 compared diabetic subjects
(8 studies in type 1 diabetes, N¼ 322; 1 study in type 2
diabetes, N¼ 263). DPI in the low-protein subjects was
0.3-0.8 g/kg/day and usual protein intake ranged from 1-2
g/kg/day. Mean follow-up ranged from 4.5 months to 4 years.
In all studies, compliance with a low DPI was poor. There was
no convincing or conclusive evidence that long-term protein
restriction delayed the progression of CKD.
The largest RCT to date was the MDRD Study.227 The
MDRD Study compared the effects of LPD and BP control on
the progression of CKD in over 800 subjects split into
2 groups. Study A compared a DPI of 1.3 g/kg/day (usual
protein intake) with 0.58 g/kg/day (LPD) in 585 subjects with
a measured GFR of 25-55ml/min/1.73 m2 and the actual
DPIs were 1.11 and 0.73 g/kg/day, respectively. Study B
randomized 255 patients with a measured GFR 13-24ml/
min/1.73 m2 to DPIs of 0.58 g/kg/day (LPD) or 0.28 g/kg/day
supplemented by keto-aminoacids (denoted by VLPD-KA),
actual DPIs were 0.69 and 0.46 g/kg/day, respectively. In each
of the randomization groups ACE-Is were allowed and were
used by 32-44% of patients. Mean follow-up was 2.2 years
and the loss of GFR was estimated by the slope of
125I-iothalamate clearance measured over 2 years. There was
no difference in GFR decline between groups in Study A and
in Study B. Although there was a somewhat faster decline in
GFR in the LPD group compared with the VLPD-KA group,
this was not significant.
A follow-up study of the original MDRD Study followed
those subjects recruited to Study B between 1989-1993 up
until the year 2000. Median duration of follow-up until
kidney failure, death, or administrative censoring was 3.2
years and median time to death was 10.6 years.290 The
authors concluded that assignment to a very LPD did not
delay progression to kidney failure, but appeared to increase
the risk of death in the long-term. The chief limitation of this
follow-up study was the lack of measurements of DPI and
nutritional measurements during the course of the long-term
follow-up period and it is therefore not known how many
patients continued with the LPD or the VLPD-KA diets
after the study concluded.
There is some evidence to suggest that higher protein
diets above the recommended daily intake may accelerate
renal functional decline in people with early CKD. In a
study of 1624 women enrolled in the Nurses0 Health Study,
Knight et al. described the effect of protein intake over an
11-year period in women with eGFR Z80ml/min/1.73 m2
(normal renal function) at baseline and those with eGFR
55-80ml/min/1.73 m2.291 DPI was measured twice during
the study period at intervals of 4 years using a semiquanti-
tative food-frequency questionnaire that inquired about
the average intake of specified foods and beverages during
the previous year. In women with normal renal function
at baseline high protein intake was not significantly
associated with change in eGFR. However in those with
eGFR 55-80ml/min/1.73 m2 at baseline, protein intake
was significantly associated with a change in eGFR of
1.69ml/min per 1.73 m2 (95% CI, 2.93 to 0.45ml/
min per 1.73 m2) per 10 g increase in protein intake.
The effect was greatest in those with the highest intake of
non-dairy animal protein.
Dietary protein restriction of o0.80 g/kg/day appears to
offer no advantage and any dietary protein restriction should
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include careful monitoring of clinical and biochemical
markers of nutritional deficiencies. A high total protein
intake, particularly high intake of non-dairy animal protein,
may accelerate renal function decline in people with CKD
and should be avoided.
International Relevance
Studies on protein restriction have not been widely tested in
different ethnicities or within cultures with low baseline
proten intake or purely vegetarian diets. Thus, the applic-
ability of statements to all regions of the world is limited.
Implications for Clinical Practice and Public Policy
Clinicians should be aware of different sources of protein, and
if lowering of protein is recommended, education and
monitoring for malnutrition should be implemented. Appro-
priate dietary counseling for CKD patients may have health-
care resource implications, although as part of a combined
strategy to manage obesity, salt intake, and diabetes may be
considered cost-effective on a population basis in certain
countries. Avoidance of malnutrition is important.
Areas of Controversy, Confusion, or Non-consensus
Data are mixed on the value of protein restriction, the values
which are achievable in general populations, and the level of
GFR at which they should be instituted. Nonetheless, the
Work Group felt that on balance there is enough data to
support a reduction in dietary protein in selected individuals.
It is important to avoid this advice in those with evidence of
or at risk of malnutrition.
Pediatric Considerations
A Cochrane review addresses this issue in children292 by
examining two RCTs with a total of 250 children to
determine the effect of protein restriction on a number of
variables. The RR of progression to ESRD in the low-protein
restricted versus normal group was 1.12 (95% CI 0.54-2.33).
At two years, progression of kidney disease was not
significant as measured by change in CrCl: mean difference
1.47ml/min/1.73 m2 (95% CI 1.19–4.14) or growth as
measured by mean weight difference: 0.13 kg (95% CI
1.10–0.84) or mean height difference: 1.99 cm (95% CI
4.84–0.86). The conclusion of the authors was that a low-
protein diet did not delay progression to kidney failure in
children, but it may be detrimental to growth.
Glycemic control
Diabetes is the leading cause of CKD worldwide. Diabetic
nephropathy occurs in 25–40% of patients with type 1 or type
2 diabetes within 20–25 years of disease onset and is an
independent risk factor for early death due to CVD. The
mortality rate in people with diabetes and urinary
ACR 430mg/g (43mg/mmol) is more than twice that in
those with normal urinary albumin levels.
The National Kidney Foundation (NKF) KDOQI Clinical
Practice Guideline for Diabetes and CKD293 has been updated
in 2012. The first three recommendations below are
reproduced verbatim from this guideline.
3.1.15: We recommend a target hemoglobin A1c (HbA1c)
of B7.0% (53mmol/mol) to prevent or delay
progression of the microvascular complications of
diabetes, including diabetic kidney disease. (1A)
3.1.16: We recommend not treating to an HbA1c target of
o7.0% (o53mmol/mol) in patients at risk of
hypoglycemia. (1B)
3.1.17: We suggest that target HbA1c be extended above
7.0% (53mmol/mol) in individuals with comor-
bidities or limited life expectancy and risk of
hypoglycemia. (2C)
3.1.18: In people with CKD and diabetes, glycemic control
should be part of a multifactorial intervention
strategy addressing blood pressure control and
cardiovascular risk, promoting the use of angio-
tensin-converting enzyme inhibition or angio-
tensin receptor blockade, statins, and antiplatelet
therapy where clinically indicated. (Not Graded)
RATIONALE
These statements are included to reflect the current evidence
that achieving a hemoglobin A1c (HbA1c) level of B7.0%
(53mmol/mol) is able to prevent the microvascular compli-
cations of diabetes, although recognizing that the major risk
for patients attaining HbA1c levels o7.0% (o53mmol/mol)
is hypoglycemia, and that this risk will be higher in people
with lower levels of kidney function.
Evidence Base
The evidence base for these statements is reviewed in the
NKF KDOQI Clinical Practice Guideline for Diabetes and
CKD: 2012 Update293 and will not be reiterated in full here. It
should be noted that the evidence that intensive glycemic
control reduces the microvascular complications of diabetes
is based almost exclusively on prevention of development of
albuminuria (ACR430mg/g or43mg/mmol) and preven-
tion of increasing albuminuria. Evidence from the three most
recent studies, Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled Evalua-
tion (ADVANCE),294 Action to Control Cardiovascular Risk
in Diabetes (ACCORD),295 and the Veterans Affairs Diabetes
Trial (VADT),296 is summarized in Table 25.
ADVANCE, ACCORD, or VADT did not show significant
benefits of more intensive glycemic control on creatinine-
based estimates of GFR. However, in the Diabetes Control
and Complications Trial (DCCT)/Epidemiology of Diabetes
Interventions and Complications (EDIC) follow-up study,
1.4% of participants in the previously intensive treatment
group and 3.6% of those in the previously conventional
treatment group developed SCr concentrations 42.0mg/dl
(177 mmol/l) (P¼ 0.01) and 0.6% versus 1.9% required
kidney replacement therapy (P o0.03).297 For patients with
type 2 diabetes, intensive treatment in the United Kingdom
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Prospective Diabetes Study (UKPDS) was associated with a
67% risk reduction for a doubling of plasma creatinine levels
at 9 years (0.71% of the intensive group and 1.76% of the
conventional group, P¼ 0.027).298
International Relevance
The incidence and prevalence of diabetes is rising around the
world and at rapid rates in developing countries. Glycemic
control is therefore one of the most important strategies
for delaying progression of CKD, irrespective of region or
country. It is recognized that not all hypoglycemic strategies
or treatments are available in all countries.
Implications for Clinical Practice and Public Policy
Practitioners should encourage glycemic control in all people
with CKD and diabetes, including referral to education
sessions and diabetic clinics where available. Public health
policies and diabetic strategies should include screening in
high-risk populations such as those with diabetes, as the
presence of CKD would confer higher risk of adverse events,
and could represent an opportunity for intensified interven-
tion with large implications for health-care.
Areas of Controversy, Confusion, or Non-consensus
Recommendations on the use of specific medications for
glycemic control (e.g., metformin and glyburide) remain
variable depending on different perspectives. These are covered
more fully in Chapter 4 on medication dosing and AKI.
Clarification of Issues and Key Points
Glycemic control improves outcomes in people with diabetes,
with or without CKD. Those with diabetes and CKD have
higher risk of adverse outcomes and therefore presumed
higher benefit from control. Many agents are renally excreted
and therefore adjustments to doses may be necessary as GFR
declines or if patients are acutely unwell (see Chapter 4 on
medication dosing).
Caveats in measuring glycemic control with HbA1C
HbA1C may not be reflective of glucose control in people
with CKD who have reduced red cell life span, and thus
should be interpreted with caution. Review of blood sugar
daily logs may be more reliable.
Clinicians should be aware that HbA1C measurements that
inform glycemic control are based on an assumed red cell life
span of 90 days. In people with CKD the RBC life span is
shortened, even if receiving erythropoiesis-stimulating agents
(ESAs). As such, measurement may only reflect glycemic
control over a shorter time period than the presumed 3
months and thus, HbA1C measurements may be falsely low.
Awareness of this may alter clinicians’ reliance on this
measurement as a long-term measure.299–304 Ongoing
research intitiatives comparing HbA1C with glycated albumin
using continuous glucose monitoring suggest that glycated
albumin may provide a more reliable index of glycemic
control in people with advanced CKD.
Pediatric Considerations
It is recommended that the Guidelines of the American
Diabetes Association305 or similar national guidelines for
diabetes management in children and adolescents, be
reviewed to address issues related to management of diabetic
children either with, or at risk of, CKD.
Salt intake
3.1.19: We recommend lowering salt intake to o90mmol
(o2 g) per day of sodium (corresponding to 5 g of
sodium chloride) in adults, unless contraindicated
(see rationale). (1C)
3.1.19.1: We recommend restriction of sodium intake
for children with CKD who have hypertension
(systolic and/or diastolic blood pressure495th
percentile) or prehypertension (systolic and/or
diastolic blood pressure 490th percentile and
o95th percentile), following the age-based
Recommended Daily Intake. (1C)
3.1.19.2: We recommend supplemental free water and
sodium supplements for children with CKD
and polyuria to avoid chronic intravascular
depletion and to promote optimal growth. (1C)
RATIONALE
In subjects with CKD, impaired excretion of sodium is often
present. High sodium intake increases BP and proteinuria,
induces glomerular hyperfiltration and blunts the response
to RAAS blockade. Lowering salt intake not only reduces BP,
but also lowers albuminuria. The importance of salt intake
in the general management of CKD patients cannot be
overemphasized, hence the need for specific statements here.
We appreciate that there are some conditions in which salt
Table 25 | Intensive versus normal glycemic control and albuminuria outcome
Study Intensified treatment versus normal treatment HbA1C goals Albuminuria outcome
ADVANCE294 6.5% (48mmol/mol) versus 7.3% (56mmol/mol) 9% k in new ACR 3-30mg/mmol (30-300mg/g)
30% k in ACR progression to 430mg/mmol (4300 mg/g)
ACCORD295 6.3% (45mmol/mol) versus 7.6% (60mmol/mol) 21% k in new ACR 3-30mg/mmol (30-300mg/g)
32% k in ACR progression to 430mg/mmol (4300mg/g)
VADT296 6.9% (52mmol/mol) versus 8.4% (68mmol/mol) 32% k in new ACR 3-30mg/mmol (30-300mg/g)
37% k in ACR progression to 430mg/mmol (4300mg/g)
Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; ACR, albumin-to-creatinine ratio; ADVANCE, Action in Diabetes and Vascular Disease: Preterax and
Diamicron Modified Release Controlled Evaluation; HbA1C, hemoglobin A1C; VADT, Veterans Affairs Diabetes Trial.
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restriction may be harmful, and hence the qualifier ‘‘unless
contraindicated.’ These conditions include salt losing ne-
phropathies and those prone to hypotension and volume
contraction who do not have heart failure.
Evidence Base
A systematic review of 16 studies addressing salt intake and
kidney disease set out to establish whether variations in
dietary sodium consumption influence renal outcomes in
people with CKD.306 Despite marked heterogeneity, the
review suggested that increased salt intake was associated
with worsening albuminuria and an increased likelihood of
reduction of GFR. Although the quality of the studies
included was insufficient to support the authors’ hypothesis
that increased salt intake is nephrotoxic, the results were
strong enough to suggest modest dietary avoidance of salt
should be encouraged in people with CKD, especially those
with hypertension and/or proteinuria. In a randomized,
double-blind, placebo-controlled trial of salt reduction in 40
Afro-Caribbean hypertensives, a salt-restricted diet (approxi-
mately 5 g daily) significantly reduced 24-hour urinary
protein excretion by 19% and led to a fall in systolic and
diastolic BP of 8mm Hg and 3mm Hg, respectively.307 The
fall in urinary protein excretion correlated with a reduction
in urinary sodium excretion, not with BP reduction.
Individuals with metabolic syndrome may be especially
sensitive to the effects of sodium intake. Hoffman and
Cubeddu examined the role of salt intake in increased BP in
109 subjects with metabolic syndrome.308 Salt restriction
from an average usual intake of 8.2 g/day to nearly 2.3 g/day
reduced the percentage of hypertensive patients from 23.8%
to 8.2%. In a six-month prospective controlled trial, 110
patients with GFR categories G4 or G5 (GFRo30 ml/min/
1.73 m2) followed a low-sodium (circa 1 g/day) diet as part of
either a LPD (0.6 g/kg/day) or very low-protein diet (VLPD)
supplemented with essential amino acids (0.35g/kg/day), or a
free diet.309 BP fell significantly in the VLPD group from
143±19/84±10 to 128±16/78±7mm Hg (Po0.0001),
despite reduction of antihypertensive drugs. The improved
BP correlated with decreased urinary sodium and the authors
concluded that the antihypertensive effect was due to
reduction of salt intake independent of actual protein intake.
Finally, a randomized controlled crossover trial in 52 non-
diabetic subjects with CKD compared the effects of a low-
sodium diet (target 50mmol [1.15 g] sodium per day) versus
a regular sodium diet (target 200mmol [4.60 g] sodium per
day) on lowering of proteinuria through RAAS blockade.310
The reduction of proteinuria by the addition of a low-sodium
diet to angiotensin-converting enzyme inhibition was
significantly larger (Po0.001) than the addition of angio-
tensin receptor blockade to angiotensin-converting enzyme
inhibition and similarly the reduction of systolic BP by the
addition of a low-sodium diet was significantly larger (P¼
0.003) than the addition of angiotensin receptor blockade.
The authors concluded that sodium restriction to a level
recommended in guidelines was more effective than dual
renin-angiotensin blockade for reduction of proteinuria and
BP in non-diabetic nephropathy.
International Relevance
Salt intake has been identified as an important driver of high
BP in all countries and in adults, thus this recommendation
is of international relevance and applicability. The relevance
and caveats to children in different situations around the
world merits further review.
Implications for Clinical Practice and Public Policy
In most developed countries, a reduction in salt intake can be
achieved by a gradual and sustained reduction in the amount
of salt added to foods by the food industry. In other countries
where most of the salt consumed comes from salt added
during cooking or from sauces, a public health campaign is
needed to encourage consumers to use less salt. The range of
sodium intake associated with improved long-term outcomes
is easily achievable and may have the potential to greatly
improve health outcomes in patients with CKD around the
world.
Areas of Controversy, Confusion, or Non-consensus
While salt restriction is of benefit on a population-basis, and
in most people with hypertension and CKD, there may be
individual conditions in which salt restriction might be
detrimental (e.g., those with salt wasting tubular disorders;
those either hypotensive in the absence of heart failure or
those prone to volume contraction). Thus while this general
statement applies to the majority of people, individualization
is required based on clinical circumstance. This may be
particularly relevant to children.
Pediatric Considerations
The suggested relative salt restrictions for children with CKD
and/or hypertension are age-based with consideration given
to both average intakes and upper limit values. The
recommended upper limit for sodium intake from which a
reduced intake could be derived is provided in Table 26.
It must also be recognized that children with CKD often
have underlying tubular conditions that predispose to
numerous electrolyte losses, including sodium. For these
children a supplemental rather than restricted sodium intake
will be required.
Table 26 | Recommended Daily Intake of sodium for healthy
children
Age Upper Limit
0-6 months No data
7-12 months No data
1-3 years 1500mg
4-8 years 1900mg
9-13 years 2200mg
14-18 years 2300mg
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Hyperuricemia
3.1.20: There is insufficient evidence to support or refute
the use of agents to lower serum uric acid
concentrations in people with CKD and either
symptomatic or asymptomatic hyperuricemia in
order to delay progression of CKD. (Not Graded)
Hyperuricemia is common in people with CKD and is
defined by urate concentrations above 7.0mg/dl (420 mmol/l)
as measured by automated enzymatic (uricase) laboratory
methods. Concentrations obtained with colorimetric
methods are approximately 1mg/dl (60 mmol/l) lower.
The Work Group believe it important to acknowledge the
accumulating body of evidence describing the association of
hyperuricemia with CKD and adverse cardiovascular out-
comes, and thus list hyperuricemia as a potential contributor
to progression. However, at the time of current writing, there
is not a reliable body of evidence from which to recommend
treatment of hyperuricemia for the specific goal of delaying
progression of CKD. Thus, the wording of this ungraded
statement is very deliberate.
RATIONALE
Observational data had implicated uric acid in the progres-
sion of CKD suggesting that adverse outcomes in people with
CKD may be improved by specific uric acid lowering therapy.
Small studies using appropriate RCT design have shown
reduced left ventricular mass, improved endothelial function,
and reduced progression of CKD in people with either
symptomatic or asymptomatic hyperuricemia and CKD.
Thus, the specific statement is intended to ensure and foster
RCTs to properly assess the risk and benefits of uric acid
lowering strategies in people with CKD.
Evidence Base
Published data implicate elevated serum uric acid (SUA)
concentrations in the progression of CKD.311–315 Reduction
of SUA by allopurinol has been reported to delay progression
of CKD in people with both diabetic and nondiabetic
CKD.316,317 Treatment of asymptomatic hyperuricemia has
also been reported to improve kidney function even in
subjects with normal levels of GFR.318,319 Both GFR and
endothelial function significantly improved in asymptomatic
hyperuricemic subjects randomly assigned to 300mg/day of
allopurinol in comparison to placebo.318 A separate double-
blind, placebo-controlled, parallel-group study in 67 people
with CKD (GFR 30-60ml/min/1.73 m2) and left ventricular
hypertrophy (LVH) randomly assigned subjects to treatment
with allopurinol (300mg/day) or placebo for 9 months.320
In comparison to placebo, the allopurinol-treated subjects
had significant reductions in left ventricular mass assessed
by magnetic resonance imaging (MRI), and improvements
in endothelial function assessed by flow-mediated dilation
of the brachial artery and in central arterial stiffness
assessed by pulse-wave analysis. Another study randomized
70 subjects with known hyperuricemia or SUA concentra-
tions Z7.0mg/dl (Z420 mmol/l) to treatment with either
allopurinol monotherapy (100-200mg/day) or a combina-
tion of allopurinol and a citrate preparation (3 g/day).321
SUA concentrations were decreased in both groups but to a
significantly lower level by combination treatment. GFR
assessed by CrCl increased in the combination therapy group
but remained unchanged in those treated with allopurinol
alone. Other uric acid lowering agents have also been
reported to improve outcomes in people with CKD. In an
8-week, placebo-controlled group comparison of rasburicase
and placebo, a single 4.5mg dose of rasburicase significantly
lowered SUA and resulted in a significant improvement in
kidney function assessed by CrCl.322 In a post hoc analysis of
1342 patients with type 2 diabetes mellitus and nephropathy
participating in the Reduction of Endpoints in Non-Insulin-
Dependent Diabetes Mellitus with the Angiotensin II
Antagonist Losartan (RENAAL) trial, Miao et al. examined
the relationship between change in SUA concentration after 6
months of treatment with losartan and doubling of SCr or
ESRD.323 Baseline SUA was 6.7mg/dl (400mmol/l) in placebo
and losartan-treated subjects. During the first 6 months,
losartan lowered SUA by 0.16mg/dl (9.5mmol/l) [95% CI
0.30-0.01; P¼ 0.031] as compared with placebo. The risk of
doubling of SCr or ESRD was decreased by 6% (95% CI 10%-
3%) per 0.5-mg/dl (30-mmol/l) decrement in SUA during the
first 6 months. This effect was independent of other risk
markers, including albuminuria.
International Relevance
There are no data to support or refute the importance of
hyperuricemia in different geographical reasons or ethnic
groups. Further study is needed.
Implications for Clinical Practice and Public Policy
There is insufficient evidence to recommend the use of uric
acid lowering agents in asymptomatic individuals for the
specific purpose of delaying CKD progression. Further large
trials are required to better understand the potential benefit
of uric acid lowering for this purpose.
Lifestyle
3.1.21: We recommend that people with CKD be encour-
aged to undertake physical activity compatible with
cardiovascular health and tolerance (aiming for at
least 30minutes 5 times per week), achieve a
healthy weight (BMI 20 to 25, according to country
specific demographics), and stop smoking. (1D)
RATIONALE
People with CKD have self-reported reduced physical
functioning and are not as aerobically fit as the general
population. Frailty, impaired physical performance, disabil-
ity, and geriatric syndromes are common among older adults
even with mild kidney disease. Reduced physical functioning
and inactivity are associated with increased mortality and
poor QOL. Obesity is associated with increased morbidity,
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mortality, and reduction in life expectancy and leads to an
increase in the incidence of diabetes, hypertension, and
dyslipidemia. Associations between smoking and CKD
suggest that smoking increases the risk of kidney failure
and that smoking cessation decreases that risk. Thus, this
statement reflects the importance of ensuring lifestyle
recommendations.
Evidence Base
CKD patients have a reduced exercise capacity and impaired
physical functioning.324–326 Moreover, reduced physical
activity is associated with increased mortality and poor
QOL in people with CKD.327–329 Regular exercise leads to
increased exercise capacity, decreased morbidity, and im-
proved health-related QOL.330–332 Exercise may reduce
cardiovascular risk through its beneficial effects on BP,
triglycerides, high-density lipoprotein cholesterol (HDL-C),
insulin resistance, and glycemic control. In ESRD, exercise
has been shown to improve arterial stiffness, BP, cardior-
espiratory function, and QOL.333–339 Less data are available
on the beneficial effects of exercise on early CKD. However, as
cardiovascular risk gradually increases with both a lower GFR
and a higher ACR, it is expected that exercise will also help to
prevent progressive CVD in less severe CKD. Indeed, in
subjects with GFR categories G3a-G4 (GFR 15–59 ml/min/
1.73 m2), long-term exercise training improved physical
impairment, arterial stiffness, and health-related QOL.340 It
has therefore been argued that exercise training is imperative
in CKD patients341 and that support programs including self-
monitoring, verbal reinforcement, and motivation should be
applied342–344 in an attempt to prevent the high cardiovas-
cular risk in CKD. A prospective study compared the benefits
of 6 months of regular walking in 40 predialysis patients with
GFR categories G4-G5 (GFRo30 ml/min/1.73 m2) (20 in an
exercising group and 20 patients who continued with usual
physical activity for comparison). Improvements noted after
1 month were sustained to 6 months in the 18 of 20 who
completed the exercise study. These included improvements
in exercise tolerance (reduced exertion to achieve the same
activity), weight loss, improved cardiovascular reactivity,
avoiding an increase in BP medication and improvements in
quality of health and life and uremic symptom scores as
assessed by questionnaire.345
In the absence of diabetes, hypertension or other
cardiovascular risk factors there has been a lack of evidence
to support a causal link between obesity and CKD.
Observational studies suggest that obesity is an independent
risk factor for CKD.346–348 The evidence in population studies
is conflicting; some studies have failed to link obesity with
decreased GFR,349,350 possibly because BMI in isolation is a
poor measure, while others suggest that CKD is indepen-
dently associated with BMI.351 It has been known for some
time that obesity is associated with secondary focal and
segmental glomerulosclerosis,352 yet significant associations
between obesity and CKD in large observational studies such
as The Framingham Heart Study disappear after adjustment
for age, gender, and cardiovascular risk factors.353 However,
systematic review and meta-analysis of weight loss interven-
tions in CKD have shown weight loss to be associated with
significant decrease in proteinuria and systolic BP with no
further decrease in GFR in people with CKD during a mean
follow-up of 7.4 months.354 A further systematic review drew
very similar conclusions. Weight loss interventions were
associated with decreased proteinuria and albuminuria by
1.7 g (95% CI 0.7-2.6 g) and 14mg (95% CI 11-17mg),
respectively (Po0.05).355 Each 1-kg weight loss was asso-
ciated with 110mg (95% CI 60-160mg; Po0.001) decrease
in proteinuria and 1.1mg (95% CI 0.5-2.4mg; P¼ 0.011)
decrease in albuminuria, respectively, independent of reduc-
tion in BP.
Multiple studies document a clear association between
smoking and renal damage in the general population,
patients with diabetes, and hypertensive patients.356 Smoking
is causally linked to cardiovascular events in the general
population and is also associated with an increased risk for
cardiovascular events in patients with CKD.357–360 Studies
investigating the beneficial effects of smoking cessation on
kidney function have all been positive.361–365
International Relevance
Exercise, weight loss and smoking cessation in CKD are
equally important in all countries and thus this recommen-
dation is of international relevance and applicability.
Implications for Clinical Practice and Public Policy
Implementation of this recommendation has no public
health cost but has the potential to make far-reaching public
health gains both in terms of population health and health-
care economics.
Additional dietary advice
3.1.22: We recommend that individuals with CKD receive
expert dietary advice and information in the
context of an education program, tailored to
severity of CKD and the need to intervene on salt,
phosphate, potassium, and protein intake where
indicated. (1B)
RATIONALE
International Relevance
The importance of lifestyle recommendations and dietary
counseling cannot be overstated. It is however recognized
that within the context of different countries, health-care
systems and jurisdictions, the degree to which these can be
implemented is variable. These recommendations serve as a
‘best practice’ suggestion.
3.2 COMPLICATIONS ASSOCIATED WITH LOSS OF KIDNEY
FUNCTION
People with CKD are prone to develop a variety of compli-
cations which reflect loss of endocrine or exocrine function of
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the kidneys. The incidence and prevalence of these complica-
tions increase with severity of CKD as defined predominantly
by GFR categories (Table 27).
It is beyond the scope of this guideline to describe each
of the complications and the proposed treatment options
for them in detail as guidance for these conditions can
be found in other documents. However, for the purpose of
completeness, the key complications and management
recommendations for people with CKD are addressed in
this section.
In addition to these complications, we have described
strategies to delay progression of CKD which are in part
predicated on the identification and management of the
clinical, metabolic, and hematologic complications. Note that
not all people with CKD will have all of the complications
and complications may not occur at the same rate or to the
same degree in individuals with the same categories of GFR
or albuminuria. Nonetheless knowledge of the common
complications and treatment options is important in the care
of CKD.
Management of Complications
Anemia in CKD. Anemia is an important complication of
CKD because it contributes significantly to the heavy
symptom burden of CKD. It has a major impact on the lives
of people with CKD but it is potentially reversible with
appropriate treatment. The guideline statements included
here are those we consider to be the key considerations for
people with non-dialysis CKD. Interested readers are referred
to the KDIGO Clinical Practice Guideline for Anemia in
CKD11 for comprehensive guidance on this topic.
Definition and identification of anemia in CKD
3.2.1: Diagnose anemia in adults and children415 years
with CKD when the Hb concentration is o13.0 g/
dl (o130 g/l) in males ando12.0 g/dl (o120 g/l) in
females. (Not Graded)
3.2.2: Diagnose anemia in children with CKD if Hb
concentration is o11.0 g/dl (o110 g/l) in children
0.5-5 years, o11.5 g/dl (115 g/l) in children 5-12
years, and o12.0 g/dl (120 g/l) in children 12-15
years. (Not Graded)
RATIONALE
These statements reflect the need to measure Hb in
people with CKD in order to detect if anemia is present,
given its association with poor outcomes and its use in
prediction models. Anemia is a common occurrence in CKD
patients, though variable in its time of presentation and
severity within individuals. Thus, the guidelines stress that
evaluation and treatment of anemia in people CKD should be
undertaken as in other individuals, and emphasize that
anemia due to CKD is a diagnosis of exclusion. Further-
more, the guidelines stress that laboratory values used for
diagnosis do not imply therapeutic thresholds or targets.
For details, consult KDIGO Clinical Practice Guideline for
Anemia in CKD.11
Evidence Base
Conventionally anemia is defined as a Hb concentration
lower than the established cutoff defined by the WHO.368
Different biological groups have different cutoff Hb values
below which anemia is said to be present, ranging from
11 g/dl (110 g/l) for pregnant women and for children
between 6 months and 5 years of age, to 12 g/dl (120 g/l)
for non-pregnant women, and to 13 g/dl (130 g/l) for men
(Table 28).
International Relevance
Globally the prevalence of anemia is 24.8% of the population,
much of this is linked to nutritional deficiency exacerbated by
Table 27 | Prevalence of CKD complications by GFR category*
derived from CKD cohorts
Complication
GFR category (ml/min/1.73 m2)
Reference
Z90 60-89 45-59 30-44 o30
Anemia1 4.0% 4.7% 12.3% 22.7% 51.5% 366
Hypertension2 18.3% 41.0% 71.8% 78.3% 82.1% 366
25(OH) Vit D deficiency3 14.1% 9.1% 10.7% 27.2% 367
Acidosis4 11.2% 8.4% 9.4% 18.1% 31.5% 366
Hyperphosphatemia5 7.2% 7.4% 9.2% 9.3% 23.0% 366
Hypoalbuminemia6 1.0% 1.3% 2.8% 9.0% 7.5% 366
Hyperparathyroidism7 5.5% 9.4% 23.0% 44.0% 72.5% 366
Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
*Note that modification of prevalence according to albuminuria categories data is
not yet available to inform this table adequately, though there are limited data to
suggest increasing prevalence of hypoalbuminemia, hypertension, anemia, and
acidosis as albuminuria category increases
1Defined as hemoglobin levels o12 g/dl (120 g/l) for women; o13.5 g/dl (135 g/l)
for men
2Defined as a systolic blood pressure Z140mm Hg, diastolic blood pressure
Z90mm Hg, or self-reported use of antihypertensive medication
3Less than 15 ng/ml [37 nmol/l] (as defined in Study for the Evaluation of Early
Kidney disease [SEEK])
4Defined as serum bicarbonate less than 21 mEq/l
5Defined as serum phosphate Z4.5mg/dl (Z1.5mmol/l)
6Defined as serum albumin less than 3.5 g/dl (35 g/l)
7Defined as PTH levels Z70 pg/ml; (Z7.4 pmol/l)
Table 28 |Hemoglobin thresholds used to define anemia
Age or gender group Hemoglobin threshold: g/dl (g/l)
Children
6 mo-5 yr 11.0 (110)
5-12 yr 11.5 (115)
12-15 yr 12.0 (120)
Non-pregnant females 415 yr 12.0 (120)
Pregnant females 415 yr 11.0 (110)
Men 415 yr 13.0 (130)
Abbreviations: mo, month; yr, year.
Reproduced with permission from World Health Organization. Worldwide pre-
valence of anaemia 1993-2005: WHO global database on anaemia.368 In: de Benoist
B, McLean E, Egli I and Cogswell M (eds), 2008; accessed: http://whqlibdoc.who.int/
publications/2008/9789241596657_eng.pdf.
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infectious disease. However, altitude, race, and smoking will
each also have an impact on Hb concentration. Hb
concentration can be expected to increase by about 0.6 g/dl
(6 g/l) in women and 0.9 g/dl (9 g/l) in men for each 1000 m
of altitude above sea level.369 Hb concentrations also vary
between races, with African-American individuals consis-
tently showing concentrations 0.5 to 0.9 g/dl (5 to 9 g/l)
lower than those of whites or Asian populations.370–372
Smoking is associated with elevated carboxyhemoglobin
levels, which are associated with a compensatory increase
in total Hb concentration. Hence, the US Centers for Disease
Control and Prevention have recommended a downwards
adjustment of 0.3 g/dl (3 g/l) for smokers.373 Thus, specific
Hb levels expected for different levels of eGFR should be
contextualized within the normal distribution of the
population.
Implications for Clinical Practice and Public Policy
The recommended thresholds for diagnosis and evaluation
of anemia should not be interpreted as being thresholds
for treatment of anemia but simply for the identification of
this complication. Practice preferences with respect to
treatment strategies should be directed according to local
resources.
Evaluation of anemia in people with CKD
3.2.3: To identify anemia in people with CKD measure Hb
concentration (Not Graded):
K when clinically indicated in people with GFR
Z60ml/min/1.73 m2 (GFR categories G1-G2);
K at least annually in people with GFR 30-59ml/
min/1.73 m2 (GFR categories G3a-G3b);
K at least twice per year in people with GFR
o30ml/min/1.73 m2 (GFR categories G4-G5).
RATIONALE
The recommendation that patients be evaluated at least
annually rests on observations from clinical trials that (in the
absence of ESA therapy) the natural history of anemia in
patients with CKD is a gradual decline in Hb concentration
over time.374–376 The exact frequency of monitoring of Hb
concentration will be influenced by kidney function, under-
lying disease process, the initial Hb concentration, and the
rate of change in Hb concentration. The latter will also be
influenced by whether or not anemia is being treated and
what type of treatment is undertaken. The statements
specifically address the need to measure Hb concentrations
at a minimum and are not intended to deter the clinician
from more frequent measurements as required for individual
circumstances.
The initial evaluation of anemia in CKD is geared towards
the exclusion of causes other than those directly related to
kidney disease (relative iron and erythropoietin deficiency);
see KDIGO Clinical Practice Guideline for Anemia in CKD11
for details.
Evidence Base
Anemia as defined above is found in people with CKD in
increasing proportions as GFR declines (Table 27). This is
due to a number of reasons, including loss of erythropoietic
hormone efficacy, production, substrate deficiency (most
notably iron), and other conditions which may contribute to
the lack of effective erythropoiesis. For a full description of
the evidence behind this statement please refer to the KDIGO
Clinical Practice Guideline for Anemia in CKD.11
International Relevance
Frequency of Hb concentration monitoring and the initial
evaluation of anemia should not differ by country, except
that causes of anemia other than those related to CKD do
differ. Nutritional deficiencies in resource-poor areas are
common, particularly iron deficiency, which is frequently
exacerbated by infectious diseases.
Implications for Clinical Practice and Public Policy
Anemia is associated with increased morbidity, mortality,
and consumption of health-care resources. The major health
consequences include poor pregnancy outcome, impaired
physical and cognitive development, increased risk of
morbidity in children, and reduced work productivity in
adults.
Treatment of anemia in CKD. The last 30 years have seen a
major transition in approach to the treatment of anemia in
people with CKD beginning with the introduction of
erythropoietin therapy into clinical practice and the sub-
sequent resurgence of interest in iron therapies. The promise
of early intervention with anemia treatment in non-dialysis
CKD suggested by observational study has been tempered
with the reality of risks of adverse cardiovascular outcomes in
RCTs. Nevertheless treatment of anemia with iron and ESAs
has an important positive role to play in the lives of people
with CKD. For the treatment of anemia in people with CKD,
we suggest clinicians refer to the KDIGO Clinical Practice
Guideline for Anemia in CKD for further details.11
The key points for practitioners to remember include the
following:
1. Work-up for anemia in CKD should include assess-
ment of secondary causes including iron deficiency.
2. Iron replacement is often effective in anemia of CKD as
initial therapy and routes of administration (intrave-
nous or oral) will be determined by clinicians, patient
preferences, and local available resources.
3. ESA therapy is not recommended in those with active
malignancy, or recent history of malignancy.
4. In most people with CKD, ESAs should not be used to
intentionally increase the Hb concentration above 11.5
g/dl (115 g/l)
5. For pediatric patients, the selection of Hb concentra-
tion at which ESA therapy is initiated should be
individualized after taking into account the poten-
tial benefits (e.g., improvement in QOL, school
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attendance/performance, and avoidance of transfusion)
and potential harms.
3.3 CKD METABOLIC BONE DISEASE INCLUDING
LABORATORY ABNORMALITIES
Changes in bone mineral metabolism and alterations in calcium
and phosphate homeostasis occur early in the course of CKD
and progress as kidney function declines (Table 27). These
changes are grouped under the umbrella term Chronic Kidney
Disease-Mineral and Bone Disorder (CKD-MBD) which
includes renal osteodystrophy and extraskeletal (vascular) calci-
fication related to abnormalities of bone mineral metabolism.
Renal osteodystrophy is the component of CKD-MBD that is
identified and quantified through bone biopsy histomorpho-
metry and includes osteitis fibrosa (hyperparathyroidism),
osteomalacia, and adynamic bone disease.
The evidence on which existing recommended guideline
treatment targets for serum concentrations of calcium,
phosphate, and parathyroid hormone (PTH), and the
strategies to achieve these targets, is exclusively observational
and thus problematic for that reason. Furthermore, very little
of the evidence is derived from patients with non-dialysis CKD.
Nevertheless we feel it is important to include here some of the
key statements relating to mineral metabolism abnormalities in
patients with non-dialysis CKD from the KDIGO Clinical
Practice Guideline for the Diagnosis, Evaluation, Prevention,
and Treatment of Chronic Kidney Disease-Mineral and Bone
Disorder (CKD-MBD) published in 2009.9 These statements
will be qualified where new data since the publication of
the CKD-MBD guidance have become available.
3.3.1: We recommend measuring serum levels of calcium,
phosphate, PTH, and alkaline phosphatase activity
at least once in adults with GFR o45ml/min/
1.73 m2 (GFR categories G3b-G5) in order to
determine baseline values and inform prediction
equations if used. (1C)
RATIONALE
As kidney function declines, abnormalities of serum calcium,
phosphate, and circulating hormones related to CKD-MBD
progress. These include PTH; 25-hydroxyvitamin D
(25(OH)D), 1,25-dihydroxyvitamin D (1,25(OH)2D), and
other vitamin D metabolites; fibroblast growth factor-23
(FGF-23); and growth hormone. At the tissue level there is
down regulation of vitamin D receptors and resistance to the
actions of PTH. Immunohistochemical abnormalities in bone
also occur early and generally precede changes in mineral
homeostasis. Extraskeletal calcification may result from
deranged mineral and bone metabolism and from the
therapies used in an attempt to correct these abnormalities.
Associations between disorders of mineral metabolism and
CVD have widened the focus of CKD-MBD to include
abnormal mineral metabolism, abnormal bone, and extra-
skeletal calcification. Once baseline values have been
obtained, the subsequent frequency of testing will be
determined on an individual basis by the actual value and
any intervention that may be introduced.
Evidence Base
There are observational studies which describe the abnorm-
alities of each of these parameters at relatively high values of
eGFR in general and high-risk population cohorts.367,377,378
Importantly, abnormalities of calcium and phosphate appear
to occur relatively later in the course of CKD than do
abnormalities in values of 1,25(OH)2D, 25(OH)D, and PTH.
Thus, the recommendation is to evaluate these parameters
relatively early in the trajectory of CKD, as an assessment of
burden of illness. In dialysis patients, the highest risks for
mortality have been reported with combinations of high
serum phosphate and calcium together with either high
PTH (RR 3.71; 95% CI 1.53-9.03; P¼ 0.004) or low PTH
(RR 4.30; 95% CI 2.01-9.22; Po0.001) compared with the
combination of high PTH with normal serum calcium and
phosphate which had the lowest mortality and was used as
the index category.379 The importance of examining combi-
nations of parameters of mineral metabolism is likely to be
no different in patients with less severe CKD, but this has not
been tested in non-dialysis populations.
There are also racial differences in the parameters of
mineral metabolism. In a multicenter cohort of 227 black and
1633 non-black patients with early CKD, blacks had similar
1,25(OH)2D levels compared with non-blacks but signifi-
cantly lower levels of 25(OH)D with higher levels of calcium,
phosphate, and PTH, and were significantly more likely to
have hyperphosphatemia than non-blacks.380 In multi-
variable analyses adjusted for age, gender, eGFR, BMI, and
diabetes, blacks had significantly lower 25(OH)D and higher
PTH levels than non-blacks. Examining the relationships
between 25(OH)D and PTH in 8415 adult participants (25%
black and 24% Mexican-American) in NHANES 2003–2004
and 2005–2006, and the relationship between 25(OH)D and
bone mineral density (BMD) in 4206 adult participants (24%
black and 24% Mexican-American) in the 2003–2004
NHANES sample, Guitierrez et al. found significant racial
differences.381 Blacks and Mexican-Americans had signifi-
cantly lower 25(OH)D and higher PTH concentrations than
whites (Po0.01 for both). Bone mineral density significantly
decreased (Po0.01) as serum 25(OH)D and calcium intake
declined among whites and Mexican-Americans, but not
among blacks (P¼ 0.2).
International Relevance
The association between black race and Hispanics and
secondary hyperparathyroidism, independent of known risk
factors, suggests that novel mechanisms may contribute to
secondary hyperparathyroidism in non-whites with CKD.
Testing for these parameters would therefore be informed by
the demographics of the population. In different countries
and regions, the ability to measure these parameters may
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vary, thus the authors of the guideline statements appreciate
that implementation of regular measurements of all these
parameters may not be possible in all jurisdictions.
Implications for Clinical Practice and Public Policy
Given there remains no clear recommendation as to
‘expected’ values in CKD nor consensus on thresholds
regarding treatment, the testing of PTH, and vitamin D
parameters would lead to substantial costs to the health-care
system. Abnormal values lead to repeat testing. There are no
data to suggest how effective or useful repeated monitoring of
abnormal values is, nor what an acceptable interval of
monitoring should be to inform care. Laboratory testing for
phosphate and calcium is relatively inexpensive, but treat-
ment and ongoing monitoring may be expensive. At the
current time, recommendations for testing frequency may be
problematic for clinical practice.
Areas of Controversy, Confusion, or Non-consensus
The inter-relationship of calcium, phosphate, and PTH, and
the potential impact of vitamin D on these mineral
metabolites and extraskeletal calcification remains an area
of research and debate among clinicians. Newer research
examining the role of FGF-23, an important molecule in
phosphate, PTH, and vitamin D homeostasis, has caused
many to question the previous focus on PTH values as
misplaced. The questions of whether vitamin D therapies are
toxic in some or all patients and what values of phosphate are
pathologic have yet to be resolved.
Pediatric Considerations
Application of guidelines related to bone health, growth, and
CKD in children is extremely complex. Numerous issues
arise, including age-related variation in normative values,
comparisons across age, sex, size, and the need to account for
pubertal changes etc., when one considers the options and
targets for evaluation and treatment.
It is recommended that in the application of any of these
specific guidelines, the reader carefully reviews the publica-
tions as they relate to pediatrics, starting with the following
two documents and then accessing the most currently
available pediatric CKD resources for the topic(s).
Recommended primary pediatric CKD-MBD resources:
K KDOQI Clinical Practice Guideline for Nutrition in
Children with CKD: 2008 Update382
K KDIGO Clinical Practice Guidelines for the Diagnosis,
Evaluation, Prevention, and Treatment of CKD-MBD9
3.3.2: We suggest not to perform bone mineral density
testing routinely in those with eGFR o45ml/min/
1.73 m2 (GFR categories G3b-G5), as information
may be misleading or unhelpful. (2B)
RATIONALE
While there is an appreciation that BMD is measured in
many elderly, this statement is intended to highlight for the
clinician the fact that the information gained from BMD in
those with reduced GFR may be false, leading to either
under- or over-treatment. Although fractures rates and
fracture-related mortality are elevated in CKD, bone
densitometry does not reliably predict fracture risk in
patients with GFR o45ml/min/1.73 m2 and neither does it
predict the type of renal osteodystrophy. Thus, BMD
measurements do not provide the information usually sought
from such testing, which is usually the basis of interventions.
Evidence Base
Decreased bone mass and changes in bone microarchitecture
occur early in CKD and worsen with progression of disease
such that patients with CKD are at increased risk of bone
fracture.383 Bone strength is determined by the density and
quality of the bone. Dual-energy x-ray absorptiometry
(DXA) scanning measures density of bone but is not able
to determine bone quality (cortical and trabecular micro-
architecture). Studies using high-resolution peripheral quan-
titative computed tomography (HR-pQCT) demonstrate
abnormalities in the cortical and trabecular microarchitec-
ture of patients with early CKD compared with healthy
control subjects.384 Although abnormalities of both DXA and
HR-pQCT associate with fractures in patients with CKD,
receiver operator characteristic curve analysis suggests that
neither technique is predictive of fracture (area under the
curve o0.75), although this improved for patients with
longer duration of CKD.385 In a cross-sectional study, the
combination of these imaging techniques with markers of
bone turnover improved prediction of fracture.386
Implications for Clinical Practice and Public Policy
A major component of fracture risk is related to fall risk, thus
reduction in fall risk may be achieved through establish-
ment of falls prevention programs. Such programs include
medication review; prevention of postural hypotension;
cardiac pacing, where appropriate; home hazard assessment
and modifications; muscle strengthening and retraining; and
treatment of vitamin D deficiency.
Areas of Controversy, Confusion, or Non-consensus
The combination of measurements of bone thickness, BMD
of femoral neck, and a history of fracture may be useful to
identify CKD patients who might benefit from fracture
prevention strategies. Prospective studies are needed to assess
the utility of these parameters for fracture prediction in the
CKD population.
Treatment of CKD-MBD
Disturbances of calcium, phosphate, vitamin D, and PTH
develop early during the course of CKD and are associated
with adverse outcomes. Studies of these and other markers of
bone mineral metabolism have improved our understanding
of disease mechanisms governing adverse outcomes of CKD-
MBD but clinical studies have yet to indicate whether or not
manipulation of these markers improves patient-level
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outcomes. In making recommendations for therapeutic
targets for mineral metabolism abnormalities, we have been
careful not to reach beyond the evidence.
3.3.3: In people with GFR o45ml/min/1.73m2 (GFR
categories G3b-G5), we suggest maintaining serum
phosphate concentrations in the normal range
according to local laboratory reference values. (2C)
3.3.4: In people with GFR o45ml/min/1.73m2 (GFR
categories G3b-G5) the optimal PTH level is not
known. We suggest that people with levels of intact
PTH above the upper normal limit of the assay
are first evaluated for hyperphosphatemia, hypo-
calcemia, and vitamin D deficiency. (2C)
RATIONALE
Higher serum phosphate concentrations are associated with
mortality and experimental data suggests that serum
phosphate concentration is directly related to bone disease,
vascular calcification and CVD. Serum phosphate, calcium,
and PTH concentrations are all inter-related in patients with
CKD. Randomized studies linking manipulation of these
parameters to clinical outcomes are lacking but systematic
review indicates that earlier phosphate control may help
reduce the early clinical consequences of CKD-MBD. Simi-
larly there is insufficient evidence that any specific phosphate
binder significantly impacts patient-level outcomes.
Evidence Base
Systematic review of serum concentrations of calcium,
phosphate, and PTH and the risk of death and CVD in
people with CKD showed that the risk of death increased
18% for every 1mg/dl (0.33mmol/l) increase in serum
phosphate concentration (RR 1.18; 95% CI 1.12-1.25).387
There was no association seen with either PTH or serum
calcium and all-cause mortality (Figure 19). Of the 327,644
subjects included in the review only 16,247 were not receiving
dialysis and of these only 8990 were people with GFR
o60ml/min/1.73 m2 not receiving RRT. In these subjects the
risk of all-cause mortality for each 1mg/dl (0.33mmol/l)
increase in serum phosphate concentration was very similar
(RR 1.29; 95% CI 1.12-1.48). As with all subjects included
there was no evidence of an association between serum
calcium concentration and all-cause mortality in people with
CKD not receiving RRT (RR 1.02; 95% CI 0.81-1.29). Data
for associations of calcium, phosphate, and PTH with
cardiovascular death were only available in one of the studies
included.
In the Multi-Ethnic Study of Atherosclerosis (MESA)
study, the associations of serum phosphate concentrations
with vascular and valvular calcification were examined in 439
people with GFR o60ml/min/1.73 m2. Each 1mg/dl
(0.33mmol/l) increase in serum phosphate concentration
was associated with a 21% (P¼ 0.002), 33% (P¼ 0.001), 25%
(P¼ 0.16), and 62% (P¼ 0.007) greater prevalence of
coronary artery, thoracic, aortic valve, and mitral valve
calcification, respectively.388 The strength of the associations
did not differ by age, race, or diabetes. Adjustment for serum
concentrations of PTH and 1,25(OH)2D did not alter the
strength of the associations.
Factors affecting gastrointestinal phosphate absorption
include 1,25(OH)2D, food content, phosphate bioavailability
and phosphate binders (natural and prescribed). Sources of
dietary phosphate are protein-rich foods, including dairy
products, meat, and fish as well as legumes, nuts, chocolates
and inorganic phosphate additives such as those found in
carbonated drinks. In a non-vegetarian Western diet, over
half the dietary intake of phosphate comes from animal
protein. Although the phosphate content of plant-derived
phosphate is higher than animal derived, its bioavailability in
terms of gastrointestinal absorption is lower.389 Inorganic
phosphate additives have the highest bioavailability. A
number of clinical studies detail benefit from dietary
phosphate and protein control in terms of secondary
hyperparathyroidism and progression of CKD in people
with moderate CKD.390 Few studies have evaluated the
impact of dietary phosphate restriction on bone disease or
vascular calcification and only one has addressed survival. In
people on hemodialysis, a post hoc analysis suggested that
more restrictive prescribed dietary phosphate was associated
with poorer indices of nutritional status and a greater need
for nutritional supplementation.391 There was a stepwise
trend toward greater survival with more liberal phosphate
prescription, which reached statistical significance among
subjects prescribed 1001 to 2000mg/d and those with no
specified phosphate restriction, raising concerns about
protein energy malnutrition with dietary phosphate restric-
tion. The means used to achieve phosphate restriction may
therefore be important.
Table 29 details the relative cost comparisons of phosphate
binders currently in clinical use for which there is observa-
tional or study trial data demonstrating their efficacy. Data
concerning comparative patient-level outcomes such as
mortality are not available.
There are a number of agents available for phosphate
binding which are listed in the table ranked in order of
relative cost, appreciating that both availability and specific
costs are country- and era-specific.
A Cochrane meta-analysis considered 60 RCTs or quasi-
RCTs (7631 participants) that assessed the effects of various
phosphate binders in adults with CKD.392 The authors
concluded that all available phosphate-binders reduced
serum phosphate concentrations in comparison to placebo
but that data to date do not support superiority of novel
non-calcium binding agents for patient-level outcomes such
as all-cause mortality and cardiovascular end points in CKD.
International Relevance
Availability of different phosphate binders differs around the
globe. Thus, recommendations as to specific agents are not
possible within the context of these statements. Similarly,
dietary phosphate intake may be different around the world,
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rendering this problem of greater or lesser significance in
different jurisdictions. Measurement of specific hormones
(PTH, vitamin D) is expensive and may not inform care
sufficiently to warrant the expense at this time.
Implications for Clinical Practice and Public Policy
Existing data support prevention of hyperphosphatemia
and associated secondary hyperparathyroidism in CKD. In
the absence of hypercalcemia, there is no indication to
prescribe phosphate-binders that are less cost-effective than
calcium-based agents. Current data are insufficient to make
recommendations about target levels of serum calcium or
PTH concentrations that should be achieved in order to
reduce mortality or cardiovascular morbidity in people with
CKD not requiring dialysis. Assay variability of PTH
and vitamin D remains problematic and this issue is
beyond the scope of this document. The practitioner and
health-care administrators are advised to appreciate this
problem in developing targets for care or thresholds for
treatment.
Areas of Controversy, Confusion, or Non-consensus
As per comments above, the data to support levels of
laboratory values for interventions, types of interventions,
and target values remain problematic. Thus recommenda-
tions for therapy remain similarly problematic and practice
varies depending on location and resource availability. Likely
correlation of symptoms with blood values and addressing
laboratory abnormalities within that context is a pragmatic
approach at the current time. The non-specialist is asked to
seek advice from local experts for best advice for specific
individuals.
The KDIGO guidelines on this subject have not been
updated at the time of the writing of this CKD guideline.
Increased Serum
Phosphorus Better
Decreased Serum
Phosphorus Better
No. of
ParticipantsPhosphorus
No. of
Cohorts
Relative Risk
(95% CI) Per
Unit Increase
All-cause mortality
4651Adequate adjustment 3 1.35 (1.16-1.57)
87 694Partial adjustment 10 1.16 (1.09-1.23)
92 345All studies combined 13 1.18 (1.12-1.25)
Cardiovascular mortality
17 326Adequate adjustment elbamitse toN1
5881Partial adjustment 2 1.14 (1.05-1.24)
23 207All studies combined 3 1.10 (1.06-1.13)
0.5 1.0 2.0
Relative Risk (95% CI)
0.5 1.0 2.0
Increased
Serum Parathyroid
Hormone Better
Decreased
Serum Parathyroid
Hormone Better
No. of
ParticipantsParathyroid hormone
No. of
Cohorts
Relative Risk
(95% CI)
All-cause mortality
17 326Adequate adjustment elbamitse toN1
83 732Partial adjustment 3 1.01 (0.99-1.03)
101 058All studies combined 4 1.01 (1.00-1.02)
Cardiovascular mortality
17 326Adequate adjustment elbamitse toN1
5041Partial adjustment elbamitse toN1
22 367All studies combined 2 1.05 (0.99-1.11)
Relative Risk (95% CI)
0.5 1.0 2.0
Increased Serum
Calcium Better
Decreased Serum
Calcium Better
No. of
ParticipantsCalcium
No. of
Cohorts
Relative Risk
(95% CI)
All-cause mortality
22 367Adequate adjustment 2 1.07 (0.91-1.24)
83 789Partial adjustment 6 1.09 (0.99-1.20)
106 156All studies combined 8 1.08 (1.00-1.16)
Cardiovascular mortality
17 326Adequate adjustment elbamitse toN1
5041Partial adjustment elbamitse toN1
22 367All studies combined 2 1.15 (1.08-1.23)
Relative Risk (95% CI)
Risks of all-cause mortality, cardiovascular mortality, and nonfatal cardiovascular events are shown per 1-mg/dL
increase in serum levels of phosphorus, 100-pg/mL increase in serum parathyroid hormone, and 1-mg/dL in-
crease in serum calcium. Summary estimates are not reported when only a single cohort contributed data. CI
indicates confidence interval.
Figure 19 | Summary estimates for risks of all-cause mortality and cardiovascular mortality associated with levels of serum
phosphorus, PTH, and calcium. PTH, parathyroid hormone. Reprinted with permission from Palmer SC, Hayen A, Macaskill P, et al. Serum
levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney
disease: a systematic review and meta-analysis. JAMA 2011; 305(11): 1119-1127.387 Copyright & (2011) American Medical Association. All
rights reserved. Accessed http://jama.jamanetwork.com/data/Journals/JAMA/18301/jrv15003_1119_1127.pdf
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We have attempted to balance current knowledge with
published guidance statements in non-CKD populations.
Clarification of Issues and Key points
Clinical trials comparing strategies such as vitamin D
replacement, dietary phosphate restriction, phosphate bin-
ders, and calcimimetics with placebo are needed to address
patient-level outcomes such as mortality and cardiovascular
morbidity in people with CKD.
Measurement of vitamin D levels is problematic and
expensive and is not advocated here.
Vitamin D supplementation and bisphosphonates in people
with CKD
3.3.5: We suggest not to routinely prescribe vitamin D
supplements or vitamin D analogs, in the absence of
suspected or documented deficiency, to suppress
elevated PTH concentrations in people with CKD
not on dialysis. (2B)
RATIONALE
This statement is intended to highlight the lack of robust data
to support either the measurement or the treatment of
vitamin D deficiency in non-dialysis CKD populations. The
statement asks the clinician to more fully evaluate the
individual situation. The internationally accepted definition
of vitamin D deficiency is a blood concentration o20 ng/ml
(o50 nmol/l). Low 25(OH)D levels are common in patients
with non-dialysis dependent CKD; concentrations of
o15 ng/ml (o37 nmol/l) occur in at least 12-15% of patients
with CKD and are more prevalent at lower GFR levels, in
institutionalized subjects, at extremes of age, and in certain
racial groups. Deficiency of 25(OH)D increases fracture
risk and is associated with increased mortality. As CKD
progresses, levels of 1,25(OH)2D progressively fall and are
closely associated with increasing PTH concentrations. In
vitamin D-deficient subjects supplementation with vitamin D
increases BMD and muscle strength, reduces risk for fractures
and falls, and reduces PTH. In the absence of deficiency,
treatment with vitamin D and related compounds has not
been shown to improve either mortality or cardiovascular
outcomes.
Evidence Base
There is a substantial amount of data to support 25(OH)D
deficiency in general and CKD populations367,393 which is
likely multifactorial. In addition to 25(OH)D deficiency,
note has been made that there is a progressive increase
in prevalence of 1,25(OH)2D deficiency with lower GFR
category, which occurs earlier than 25(OH)D deficiency
(Figure 20).
No relationship between 25(OH)D levels and 1,25(OH)2D
levels was apparent but there was a strong association
between 1,25(OH)2D deficiency and PTH concentration. Of
particular note, a higher urinary ACR was associated with
lower levels of 1,25(OH)2D at GFR values of o60ml/min/
1.73 m2.
Table 29 | Phosphate binding agents in routine clinical practice and their ranked cost
Agent Dose/day Clinical experience and evidence base
Ranked
cost*
Aluminium hydroxide 1.425-2.85 g Extensive clinical experience in CKD and ESRD, no RCT comparison versus placebo.
Aluminium accumulates in bone and neural tissue with long-term use, avoids
calcium
1
Calcium citrate 1.5-3 g Limited trial evidence in ESRD. Reduction in phosphate and elevation in calcium
dose-dependent
2
Magnesium carbonate 0.7-1.4 g (plus calcium
carbonate 0.33-0.66 g)
Short-term RCT evidence in ESRD, less hypercalcemia 3
Calcium acetate and
Magnesium carbonate
combination
Calcium acetate 435mg
plus
Magnesium carbonate
235mg, 3-10 tablets daily
Short-term RCT evidence in ESRD, less hypercalcemia 3
Calcium carbonate 3-6 g Extensive clinical experience in CKD and ESRD, limited RCT evidence versus placebo.
Reduction in phosphate and elevation in calcium both dose-dependent
4
Calcium acetate 3-6 g Extensive clinical experience in ESRD; RCT evidence comparing to other binders.
Reduction in phosphate and elevation in calcium dose-dependent but less than with
calcium carbonate
4
Lanthanum carbonate 3 g Extensive prospective cohort evidence, RCT evidence compared to other phosphate
binders. Potential for accumulation in bone and other tissues, avoids calcium
5
Sevelamer-HCl 4.8-9.6 g Extensive prospective cohort evidence in ESRD; RCT evidence compared to other
phosphate binders; surrogate and patient-centered outcomes, avoids calcium
6
Sevelamer carbonate 4.8-9.6 g RCT evidence compared to other phosphate binders; equivalency studies compared
to sevelamer-HCl, avoids calcium
6
Abbreviations: CKD, chronic kidney disease; ESRD, end-stage renal disease; RCT, randomized controlled trial.
*The average annual cost of aluminium hydroxide in the UK, for example, is d51/year equivalent to US$84/year. The cost of lanthanum and sevelamer in the UK is 38-42 times
higher and the cost of calcium and magnesium-based binders 5-7 times higher than aluminium hydroxide (All drug costs derived from 2011 British National Formulary list
prices).
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The potential importance of these deficiencies has been
illustrated in a number of studies examining the relationship
between low levels of 25(OH)D and 1,25(OH)2D and all-cause
and cardiovascular mortality in a different cohorts.393,394
Despite the associations with mortality, systematic review of
published data to date on vitamin D supplementation in
patients with CKD not on dialysis has only shown an
improvement in biochemical end points. A series of publica-
tions395,396 have attempted to summarize the efficacy of
vitamin D therapy on biochemical, bone, cardiovascular, and
mortality outcomes in people with CKD and not requiring
dialysis. No formulation, route, or schedule of vitamin D
compound was found to alter the mortality risk or need for
dialysis although vitamin D compounds significantly lowered
serum PTH concentrations. None of the studies assessed
reported outcomes related to CVD, bone disease, or mortality.
International Relevance
The importance of vitamin D deficiency has been addressed in
both general and CKD populations. Specific populations have
been identified as more likely to be vitamin D deficient
depending on cultural and environmental factors; estimates of
worldwide prevalence of vitamin D deficiency range from
25-60%. CKD populations within high-risk areas may be parti-
cularly vulnerable. The interplay between loss of kidney func-
tion and exacerbation of vitamin D deficiency is not known.
Implications for Clinical Practice and Public Policy
Vitamin D supplementation improves biochemical end
points similar to active vitamin D analogs with a lower
burden of costs and side effects. Measurement of serum
25(OH)D is expensive and in the CKD population with
vitamin D deficiency, simple vitamin D replenishment is all
that is indicated until new evidence becomes available. Except
for education or research purposes, there is no need to
measure vitamin D levels in general practice.
Areas of Controversy, Confusion, or Non-consensus
The appropriate dose and formulation of vitamin D, target
range for treatment, frequency, route of administration, and
safety at different severities of CKD remain to be determined.
3.3.6: We suggest not to prescribe bisphosphonate treat-
ment in people with GFR o30ml/min/1.73 m2
(GFR categories G4-G5) without a strong clinical
rationale. (2B)
RATIONALE
The risk-benefit ratio of bisphosphonates has not been well
studied in CKD populations. Indications for bisphosphonate
therapy include osteoporosis, corticosteroid therapy, malig-
nant disease and Paget’s disease. In people with CKD and
GFR categories 460ml/min/1.73 m2 with osteoporosis and/
or at high risk of fractures, and in people with GFRs between
30-60ml/min/1.73 m2 with normal PTH, osteoporosis
and/or at high risk of fracture, treatment should be the same
as for the general population (although dose modification
may be necessary, see Table 30).
In people with CKD at lower categories of GFR
(o30-35ml/min/1.73 m2), the correct diagnosis of osteo-
porosis becomes increasingly complex and other forms of
renal osteodystrophy requiring alternative management
strategies to osteoporosis require exclusion before treatment
with bisphosphonates is considered. In people with adynamic
renal bone disease, more likely at lower GFR categories, there
is a lack of evidence of either harm or benefit of bisphos-
phonates on bone strength or vascular calcification.
Evidence Base
Bisphosphonates increase BMD, reduce bone turnover, and
reduce the risk of fragility fractures. The bioavailability of
intravenous bisphosphonate formulations is 100% but the
bioavailability of oral formulations is only 1-5%. Approxi-
mately 50-80% of available bisphosphonate is taken up by
bone and the remaining 20-50% is excreted in urine without
being metabolized. Although oral bisphosphonates have not
been shown to adversely affect kidney function in people
with GFRs as low as 15ml/min/1.73 m2, in post hoc analysis
of clinical trial data their safety and efficacy below
GFRs of 30ml/min/1.73 m2 have not been well-validated
and intravenous bisphosphonates have been implicated
in nephrotoxicity, especially when rapidly infused
(Table 30).9,397,398 Thus, from a patient’s safety perspective,
the statement serves to limit exposure of those with abnormal
kidney function to these agents.
International Relevance
Given cost and clinical practice variation, the use of
bisphosphonates varies around the world. Thus, this state-
ment may be less applicable in different jurisdictions.
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Figure 20 |Prevalence of deficiency of 1,25(OH)2D3, 25(OH)D3,
and secondary hyperparathyroidism by GFR intervals. GFR,
glomerular filtration rate; PTH, parathyroid hormone. Adapted by
permission from Macmillan Publishers Ltd: Kidney International.
Levin A, Bakris GL, Molitch M, et al.367 Prevalence of abnormal
serum vitamin D, PTH, calcium, and phosphorus in patients with
chronic kidney disease: results of the study to evaluate early
kidney disease. Kidney Int 2007; 71: 31-38; accessed http://
www.nature.com/ki/journal/v71/n1/pdf/5002009a.pdf
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Implications for Clinical Practice and Public Policy
Given the widespread use of bisphosphonates in developed
countries, especially in older women who are also likely to
have some degree of kidney dysfunction, the cessation of
bisphosphonates in that group may be problematic. There is
a need to monitor clinical practice and understand the
implications of this recommendation for large populations,
who may or may not be deriving benefit from these agents.
Areas of Controversy, Confusion, or Non-consensus
Despite these concerns, primary care data from the USA suggest
that prescription of bisphosphonates is common in people with
CKD. Even in the subset with GFR o30ml/min/1.73 m2,
bisphosphonate use was no less prevalent than in the non-CKD
population.399 People with CKD in this study were nearly seven
times more likely to receive a bisphosphonate than active
vitamin D. Similar uncertainty about the efficacy and safety of
such treatment for people with CKD was demonstrated in a
study of people under the care of a UK renal unit.400 Half of
all people prescribed bisphosphonates had a GFRo30ml/min/
1.73 m2 and yet 50% of people with higher GFRs and
documented osteoporosis were not prescribed bisphosphonates.
Clarification of Issues and Key Points
Further study is required to elucidate whether or not
bisphosphonates, through reduction of bone turnover in
people with pre-existing low bone turnover states, would be
beneficial or harmful both for bone and vascular calcification.
3.4 ACIDOSIS
The prevalence and severity of metabolic acidosis in people
with CKD progressively rises as GFR falls (Table 27).
Adaptations in acid excretion by the kidneys initially prevent
a fall in serum bicarbonate concentration but as GFR
continues to decline below 40ml/min/1.73 m2, metabolic
acidosis commonly develops.
3.4.1: We suggest that in people with CKD and serum
bicarbonate concentrations o22mmol/l treatment
with oral bicarbonate supplementation be given to
maintain serum bicarbonate within the normal
range, unless contraindicated. (2B)
RATIONALE
Serum bicarbonate concentrations less than 22mmol/l are
associated with increased risk of CKD progression and
increased risk of death. Conversely, high serum bicarbonate
concentrations greater than 32mmol/l are associated with
increased risk of death irrespective of the level of kidney
function. Small studies of alkali supplementation have shown
reduction in progression of CKD and improved nutritional
status in people with CKD. This statement is therefore
worded to reflect the potential benefits of oral bicarbonate
supplementation to maintain serum bicarbonate concentra-
tions within the normal range, but the word ‘suggest’ in the
statement reflects the lack of robust evidence base on which
to support this statement.
Evidence Base
Chronic metabolic acidosis is associated with increased
protein catabolism, uremic bone disease, muscle wasting,
chronic inflammation, impaired glucose homeostasis, im-
paired cardiac function, progression of CKD, and increased
mortality.401–410 The suggestion that treatment of acidosis
may be beneficial was first made by Richard Bright,411 later
Table 30 | Summary data for bisphosphonates and CKD
Agent Indications
Dose, frequency and route of
administration
Special considerations for CKD and clinical trial
notes
Alendronate Postmenopausal osteoporosis
Corticosteroid use
10mg daily, oral
70mg weekly, oral
GFR o35ml/min/1.73 m2: not recommended
No reported adverse events specific to CKD
Clodronate Malignancy-related bone disease 1.6-3.2 g daily, oral GFR o10ml/min/1.73 m2: contraindicated
GFR 10–30ml/min/1.73 m2: reduce dose by 50%
Etidronate Postmenopausal osteoporosis
Corticosteroid use
Paget’s disease
400mg daily for 14 days, oral
5-10mg/kg daily for up to 6 months
Mild renal impairment: reduce dose
Moderate or severe renal impairment: avoid
No data in CKD
Ibandronate Malignancy-related bone disease
Postmenopausal osteoporosis
150mg monthly, oral
3mg every 3-months intravenous
GFR o30ml/min/1.73 m2: not recommended
No reported adverse events specific to CKD
Pamidronate Malignancy-related bone disease
Paget’s disease
15-60mg single dose, intravenous
30mg weekly for 6 weeks, intravenous
GFR o30ml/min/1.73 m2: avoid
AKI reported
Risedronate Postmenopausal osteoporosis
Corticosteroid use
Paget’s disease
5mg daily, oral
35mg weekly, oral
GFR o30ml/min/1.73 m2: contraindicated
No reported adverse events specific to CKD
Tiludronate Paget’s disease 400mg daily for 3 months CrCl o30ml/min: contraindicated
No data in CKD
Zoledronate Malignancy-related bone disease
Postmenopausal osteoporosis
Paget’s disease
4-5mg single dose, intravenous GFR o30ml/min/1.73 m2: avoid
GFR o60ml/min/1.73 m2:
graded dose reduction
No data in CKD, AKI reported in non-CKD
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; CrCl, creatinine clearance; GFR, glomerular filtration rate.
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taken up enthusiastically by Arthur Osman412 and further
explored by Lyon et al. who conducted a form of crossover
study of supplementation with bicarbonate in 17 people with
moderate kidney failure and suggested that treatment with
alkali might preserve kidney function.413 Rustom et al.
described a reduction in proximal renal tubular catabolism
and markers of tubular injury after oral NaHCO3 in 11
people with mild/moderate renal impairment (mean
51Cr-EDTA GFR 46.2± 6.0ml/min/1.73 m2) and proteinuria
(3.2 ± 0.8 g/24 hours).414 They suggested that oral sodium
bicarbonate may protect the proximal renal tubule and help
delay kidney disease progression. Mathur et al. randomized
40 subjects with mild to moderate CKD to oral bicarbonate
(1.2 mEq/kg of body weight) or placebo for 3 months and
suggested that correction of metabolic acidosis significantly
attenuates the rise in blood urea.415 A larger study randomly
assigned 134 adults with moderate to severe CKD (CrCl 15 to
30ml/min/1.73 m2) and serum bicarbonate 16 to 20mmol/l
to either supplementation with oral sodium bicarbonate
(1.82 ± 0.80 g/day) or standard care for 2 years.416 Primary
end points were rate of kidney function decline, the
proportion of subjects with rapid decline of kidney function
(43ml/min/1.73 m2/yr), and ESRD (CrCl o10ml/min
[o0.17ml/s]). Secondary end points were DPI, normalized
protein nitrogen appearance, serum albumin, and mid-arm
muscle circumference. Serum bicarbonate increased signifi-
cantly in the bicarbonate group but despite the associated
sodium load there was no difference in BP control,
prescription of antihypertensives and loop diuretics, or
hospitalization for heart failure compared with the control
group. The decline in CrCl was significantly slowed in the
bicarbonate group compared with controls (5.93 versus
1.88ml/min/1.73 m2, Po0.0001), rapid progression was less
prevalent (9 versus 45%, RR 0.15; 95% CI 0.06-0.40;
Po0.0001), and fewer subjects developed ESRD (6.5 versus
33%, RR 0.13; 95% CI 0.04-0.40; Po0.001). Nutritional
parameters also improved significantly with bicarbonate
supplementation. In a non-randomized study the effects of
supplementation of 1mmol of bicarbonate equivalent per kg
body weight per day for 2 years using oral sodium citrate in
30 subjects with hypertensive nephropathy was compared
with 29 control subjects.417 There were no statistically
significant differences in baseline demographic data, systolic
BP, venous bicarbonate levels, or parameters of kidney
function between the two groups. All subjects were receiving
angiotensin-converting enzyme inhibition throughout the
study and BP was controlled to similar levels in both groups
in a 6-month run-in period prior start of study. In those
treated with oral sodium citrate, urine endothelin-1 excretion
and N-acetyl-b-D glucosaminidase were each significantly
lower while the rate of GFR decline was significantly slower
after 24 months of treatment compared to the control group.
International Relevance
Alkali supplementation appears to be a promising low-cost,
high-benefit adjunct treatment for patients with CKD and
may be accessible to all populations. It is not known how
prevalent acidosis is among different communities or
countries around the world.
Implications for Clinical Practice and Public Policy
The use of sodium bicarbonate or calcium carbonate as a
source of alkali should not present financial hardships in
most practices or jurisdictions.
Areas of Controversy, Confusion, or Non-consensus
A potential concern regarding treatment of patients with
CKD with sodium bicarbonate or sodium citrate is the
possible associated sodium loading. A crossover study of
200mmol/day (17 g/day) of sodium bicarbonate versus
200mmol/day (12 g/day) of sodium chloride in 10 subjects
with severe CKD (CrCl 2.5-16.8ml/min [0.04-0.28ml/s]) on
an extremely low-sodium diet showed that sodium chloride
but not sodium bicarbonate produced an increase in weight
and BP.418 A subsequent follow-up study suggested that if
dietary sodium chloride intakes are near maximum tolerance,
then sodium bicarbonate supplementation should be accom-
panied by reductions in sodium chloride intake to maintain
sodium balance.419 Given the lack of large and long-term
trials, many are still not convinced that this is a reasonable
recommendation, and is thus controversial. We would like to
ensure that individual clinicians are aware of the controversy
rather than making no statement at all.
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